Stock Picks Today: Marico, Lupin, Abbott India And More On Brokerages' Radar

Marico Ltd., Lupin Ltd., and Abbott India Ltd. are among companies that have drawn commentary from top brokerages on Monday. Analysts have tweaked share price targets and future outlook after some of these companies announced their December quarter results.

Brokerages On Marico

HSBC

• Maintain Buy with TP of Rs 900.
• Accelerated diversification mode on.
• Revised target for Foods & Premium personal care share to 33% on India revenues by FY30 Vs earlier 25% by FY27.
• Profitability targets reaffirmed; appreciate diversification efforts, preferred name in FMCG.

Morgan Stanley

• Maintain Equal-Weight with target price of Rs 788.
• Plans to lift foods + premium personal care share from 22% (FY24) to 33% (FY30).
• Foods business to grow fast with 31% CAGR (FY24–27) and ~19% (FY27–30).
• EBITDA margins in digital-first PPC to reach double digits by FY27 and teens by FY30.
• Diversification is essential for Marico to achieve 13–14% consolidated growth.
• Open to acquisitions in mass foods and personal care.
• Diversification is key to cos goal of 13–14% consolidated growth.

Jefferies

• Maintains buy with target price of Rs 900.
• Announced 3 acquisitions in quick succession.
• Strengthen its digital-first foods and BPC portfolio in India and overseas.
• Company aims to 3–3.5x revenues of acquired brands by FY30.
• Strong past record with Beardo & Plix boosts confidence.

ALSO READ: Five Stocks To Buy Or Sell: IndusInd Bank, PNB, Lupin, And More | February 16, 2026

CLSA On Abbott India

• Maintain Outperform; Hike TP to Rs 32560 from Rs 30330.
• Margins and profitability remain strong.
• Key products grow steadily but few new launches to impact topline trajectory.
• Believe the company's leading position in its power brands will continue to drive topline growth.
• This will be further supported by new product launches.
• Expect a 10% revenue Cagr over FY26-28.

Brokerages On Lupin

Nomura

• Maintain Buy with TP of Rs 2580.
• Q3 ahead of estimates on strong US sales.
• Lupin received approval for biosimilar pegfilgrastim, which is yet to be launched.

Morgan Stanley

• Maintain Equal-weight; Hike TP to Rs 2,386 from Rs 2,221.
• Impressive quarter; peak margin.
• A sharp beat was driven by strong US gJynarque and gMyrbetriq sales.
• FY26 EBITDA margin guidance was raised to 27-28%.
• FY27 margin is still seen at 24–25%.
• gMyrbetriq, gJynarque and gSpiriva generic sales peak out seen in FY26.

Citi

• Maintain Buy; Hike TP to Rs 2540 from Rs 2260.
• An all round performance in Q3.
• Strong traction in the US business.
• Management upbeat on near- to medium-term growth drivers.
• Remain constructive as India business is seeing strong momentum.

Morgan Stanley On India Consumer

• Vedant Fashion – Downgrade to Underweight from Equal-weight; Cut TP to Rs 400 from Rs 642.
• AB Lifestyle – Maintain Overweight with TP of Rs 176.
• Vedant's weak growth trends for three years.
• This indicates fundamental challenges to the business model and competitive environment.
• General weak demand conditions and fluctuations in wedding calendars also impact earnings.
• Valuation derating could continue.
• Prefer AB Lifestyle; better play on improving growth momentum.

Citi On Brokers

• RBI has issued draft guidelines for commercial banks and SFBs for exposure towards capital markets
• Expect rise in capital requirements for capital market intermediaries
• See incremental focus for capital market entities or individuals to tap into non-traditional financing route
• This will pave the way for faster growth in structured products or lending avenues for wealth managers
• See the likelihood of moderation in overall trading activity in select cohorts (ex. proprietary trading)
• It is premature to gauge overall P&L impact at this juncture
• Transactional based plays like brokers, clearing members and exchanges are likely to be impacted, in our view

Morgan Stanley On Brainbees Solutions

• Downgrade to Equal-weight from Overweight; Cut TP to Rs 300 from Rs 365
• Q3 Missed expectations on growth and margin
• Visibility of a meaningful recovery in growth is limited for the near term
• Believe a recovery in stock price would follow a growth recovery
• At current levels, think risk/reward is balanced
• Await better visibility on sustained improvement in performance

Brokerages On Biocon

Goldman Sachs

• Maintain Neutral with TP of Rs 375.
• Generics outperformance continues, focus on Biosimilar launches in FY27.
• Margins surprised negatively due to higher SG&A.
• Steady Biosimilar performance.

HSBC

• Maintain Buy; Cut TP to Rs 445 from Rs 455.
• Focus on execution post BBL integration.
• Blip in biosimilars sales in Q3 due to platform upgrade.
• Improved setup enables it to better serve demand ahead.
• Outlook intact for biosimilars on new launches.
• Generics segment should see pick-up on differentiated new launches.
• Market share gain for new biosimilar launches remains the key.

Kotak Institutional Equities

• Maintains Reduce with target price of Rs 375.
• Soft Q3, mainly due to temporary biosimilar supply disruptions.
• Generics grew 24% YoY, helped by Liraglutide launches in Europe.
• Biosimilars sales hit by facility upgrades; recovery expected from Q4FY26.
• Expects ~19% biosimilars sales CAGR (FY25–28).
• Syngene to grow again from FY27 onward despite near-term softness.

Jefferies on Siemens Energy India

• Rated buy with target price of Rs 3700; upside 35%
• Strong beat: Q3 margins 455 bps above estimates at 24%
• Order book up 38% YoY, supporting future growth.
• Board approved Rs 2,100 crore greenfield investment for 30,000 MVA transformer capacity.
• Expansion likely doubles current capacity, showing strong growth confidence.
• Expect 40% EPS CAGR (FY25–28E) driven by power T&D capex and operating leverage.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.